Design and generation of humanized single-chain Fv derived from mouse hybridoma for potential targeting application

Journal article

Authors/Editors

KANOKWAN POOMPUTSA

Strategic Research Themes

No matching items found.

Publication Details

Author list: Khantasup K., Chantima W., Sangma C., Poomputsa K., Dharakul T.

Publisher: Mary Ann Liebert Inc.

Publication year: 2015

Volume number: 34

Issue number: 6

Start page: 404

End page: 417

Number of pages: 14

ISSN: 2167-9436

eISSN: 2167-9436

URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84951771744&doi=10.1089%2fmab.2015.0036&partnerID=40&md5=30a54aca77c7163cd42eedb38fc49059

Languages: English-Great Britain (EN-GB)

View on publisher site

Abstract

Single-chain variable antibody fragments (scFvs) are attractive candidates for targeted immunotherapy in several human diseases. In this study, a concise humanization strategy combined with an optimized production method for humanizing scFvs was successfully employed. Two antibody clones, one directed against the hemagglutinin of H5N1 influenza virus, the other against EpCAM, a cancer biomarker, were used to demonstrate the validity of the method. Heavy chain (VH) and light chain (VL) variable regions of immunoglobulin genes from mouse hybridoma cells were sequenced and subjected to the construction of mouse scFv 3-D structure. Based on in silico modeling, the humanized version of the scFv was designed via complementarity-determining region (CDR) grafting with the retention of mouse framework region (FR) residues identified by primary sequence analysis. Root-mean-square deviation (RMSD) value between mouse and humanized scFv structures was calculated to evaluate the preservation of CDR conformation. Mouse and humanized scFv genes were then constructed and expressed in Escherichia coli. Using this method, we successfully generated humanized scFvs that retained the targeting activity of their respective mouse scFv counterparts. In addition, the humanized scFvs were engineered with a C-terminal cysteine residue (hscFv-C) for site-directed conjugation for use in future targeting applications. The hscFv-C expression was extensively optimized to improve protein production yield. The protocol yielded a 20-fold increase in production of hscFv-Cs in E. coli periplasm. The strategy described in this study may be applicable in the humanization of other antibodies derived from mouse hybridoma. ฉ Mary Ann Liebert, Inc. 2015.

Keywords